Clinical significance of fragmented red cells after allogeneic bone marrow transplantation
To clarify the clinical significance of the presence of fragmented red cells (FRC) after allogeneic bone marrow transplantation (BMT), we measured the incidence and degree of FRC and their relationships to clinical features. The percentages of FRC (%FRC) were measured in 50 patients on weeks -2, 0,...
Gespeichert in:
Veröffentlicht in: | International journal of hematology 2003-02, Vol.77 (2), p.180-184 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 184 |
---|---|
container_issue | 2 |
container_start_page | 180 |
container_title | International journal of hematology |
container_volume | 77 |
creator | KANAMORI, Heiwa TAKAISHI, Yumiko ISHIGATSUBO, Yoshiaki TAKABAYASHI, Maki TANAKA, Masatsugu YAMAJI, Satoshi TOMITA, Naoto FUJIMAKI, Katsumichi FUJISAWA, Shin WATANABE, Shinichiro MATSUZAKI, Michio |
description | To clarify the clinical significance of the presence of fragmented red cells (FRC) after allogeneic bone marrow transplantation (BMT), we measured the incidence and degree of FRC and their relationships to clinical features. The percentages of FRC (%FRC) were measured in 50 patients on weeks -2, 0, 2, 4, 6, 8, 10, and 12. The %FRC in pre-BMT patients (mean, 0.52%; range, 0.04%-1.56%) was higher than in healthy control subjects (mean, 0.08%; range, 0.02%-0.27%). The highest %FRC (> or = 1.3%) were seen in 2 pre-BMT and 17 post-BMT patients. Eight patients who developed thrombotic microangiopathy (TMA) showed %FRC values that were significantly higher than those in patients without TMA. However, the timing of elevated %FRC was delayed until several days after the onset of intravascular hemolysis and/or a drop in platelet count. Of the patients who did not experience TMA, 5 patients with infection and 4 patients with acute graft-versus-host disease (GVHD) also showed significant elevation of %FRC during the clinical course. Furthermore, multivariate analysis results demonstrated that TMA and infection had a statistically significant effect on the high value of %FRC. These findings indicate that the appearance of FRC is a common phenomenon in patients undergoing BMT and is not a predictive factor for the early diagnosis of TMA, although FRC is one of the main laboratory findings in TMA. Furthermore, an increased %FRC is seen in other post-BMT clinical settings, such as infection and acute GVHD. |
doi_str_mv | 10.1007/BF02983218 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73090048</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1879945031</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-697c031cd6cfc4009a4e9f8e16106ea92b5bd11e6103af1c506ab8d6440000d93</originalsourceid><addsrcrecordid>eNpd0E1rGzEQBmBRGhLn49IfUEQhORQ2HUkraXVsTZIGAr2kl1wWrXZkZNaSK60p-fdRsMGQw6ARPAwzLyFfGNwyAP3j1z1w0wnOuk9kwTolG6F1-5kswHDZSM3gjJyXsgZgGlp9Ss4YV1x3Ui7Iy3IKMTg70RJWMfjaRoc0eeqzXW0wzjjSXMvhNBVq_YyZ2mlKK4wYHB1SRLqxOaf_dM42lu1k42znkOIlOfF2Knh1eC_I3_u75-Xv5unPw-Py51PjhBFzo4x2IJgblfOuBTC2ReM7ZIqBQmv4IIeRMaxfYT1zEpQdulG11QKMRlyQm_3cbU7_dljmfhPK-7o2YtqVXgswAG1X4bcPcJ12Odbdes606DgXuqLve-RyKiWj77c51ANfewb9e9z9Me6Kvx4m7oYNjkd6yLeC6wOwpYZcM40ulKNrJQempHgDtQ6Ggg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217382237</pqid></control><display><type>article</type><title>Clinical significance of fragmented red cells after allogeneic bone marrow transplantation</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>KANAMORI, Heiwa ; TAKAISHI, Yumiko ; ISHIGATSUBO, Yoshiaki ; TAKABAYASHI, Maki ; TANAKA, Masatsugu ; YAMAJI, Satoshi ; TOMITA, Naoto ; FUJIMAKI, Katsumichi ; FUJISAWA, Shin ; WATANABE, Shinichiro ; MATSUZAKI, Michio</creator><creatorcontrib>KANAMORI, Heiwa ; TAKAISHI, Yumiko ; ISHIGATSUBO, Yoshiaki ; TAKABAYASHI, Maki ; TANAKA, Masatsugu ; YAMAJI, Satoshi ; TOMITA, Naoto ; FUJIMAKI, Katsumichi ; FUJISAWA, Shin ; WATANABE, Shinichiro ; MATSUZAKI, Michio</creatorcontrib><description>To clarify the clinical significance of the presence of fragmented red cells (FRC) after allogeneic bone marrow transplantation (BMT), we measured the incidence and degree of FRC and their relationships to clinical features. The percentages of FRC (%FRC) were measured in 50 patients on weeks -2, 0, 2, 4, 6, 8, 10, and 12. The %FRC in pre-BMT patients (mean, 0.52%; range, 0.04%-1.56%) was higher than in healthy control subjects (mean, 0.08%; range, 0.02%-0.27%). The highest %FRC (> or = 1.3%) were seen in 2 pre-BMT and 17 post-BMT patients. Eight patients who developed thrombotic microangiopathy (TMA) showed %FRC values that were significantly higher than those in patients without TMA. However, the timing of elevated %FRC was delayed until several days after the onset of intravascular hemolysis and/or a drop in platelet count. Of the patients who did not experience TMA, 5 patients with infection and 4 patients with acute graft-versus-host disease (GVHD) also showed significant elevation of %FRC during the clinical course. Furthermore, multivariate analysis results demonstrated that TMA and infection had a statistically significant effect on the high value of %FRC. These findings indicate that the appearance of FRC is a common phenomenon in patients undergoing BMT and is not a predictive factor for the early diagnosis of TMA, although FRC is one of the main laboratory findings in TMA. Furthermore, an increased %FRC is seen in other post-BMT clinical settings, such as infection and acute GVHD.</description><identifier>ISSN: 0925-5710</identifier><identifier>EISSN: 1865-3774</identifier><identifier>DOI: 10.1007/BF02983218</identifier><identifier>PMID: 12627855</identifier><language>eng</language><publisher>Tokyo: Springer</publisher><subject>Adolescent ; Adult ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Bone Marrow Transplantation - adverse effects ; Bone marrow, stem cells transplantation. Graft versus host reaction ; Case-Control Studies ; Erythrocytes - pathology ; Female ; Hemolysis ; Hemolytic-Uremic Syndrome - blood ; Hemolytic-Uremic Syndrome - diagnosis ; Hemolytic-Uremic Syndrome - etiology ; Humans ; Incidence ; Infection - blood ; Male ; Medical sciences ; Middle Aged ; Predictive Value of Tests ; Purpura, Thrombotic Thrombocytopenic - blood ; Purpura, Thrombotic Thrombocytopenic - diagnosis ; Purpura, Thrombotic Thrombocytopenic - etiology ; Risk Factors ; Time Factors ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy ; Transplantation, Homologous</subject><ispartof>International journal of hematology, 2003-02, Vol.77 (2), p.180-184</ispartof><rights>2003 INIST-CNRS</rights><rights>The Japanese Society of Hematology 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-697c031cd6cfc4009a4e9f8e16106ea92b5bd11e6103af1c506ab8d6440000d93</citedby><cites>FETCH-LOGICAL-c393t-697c031cd6cfc4009a4e9f8e16106ea92b5bd11e6103af1c506ab8d6440000d93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14520165$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12627855$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KANAMORI, Heiwa</creatorcontrib><creatorcontrib>TAKAISHI, Yumiko</creatorcontrib><creatorcontrib>ISHIGATSUBO, Yoshiaki</creatorcontrib><creatorcontrib>TAKABAYASHI, Maki</creatorcontrib><creatorcontrib>TANAKA, Masatsugu</creatorcontrib><creatorcontrib>YAMAJI, Satoshi</creatorcontrib><creatorcontrib>TOMITA, Naoto</creatorcontrib><creatorcontrib>FUJIMAKI, Katsumichi</creatorcontrib><creatorcontrib>FUJISAWA, Shin</creatorcontrib><creatorcontrib>WATANABE, Shinichiro</creatorcontrib><creatorcontrib>MATSUZAKI, Michio</creatorcontrib><title>Clinical significance of fragmented red cells after allogeneic bone marrow transplantation</title><title>International journal of hematology</title><addtitle>Int J Hematol</addtitle><description>To clarify the clinical significance of the presence of fragmented red cells (FRC) after allogeneic bone marrow transplantation (BMT), we measured the incidence and degree of FRC and their relationships to clinical features. The percentages of FRC (%FRC) were measured in 50 patients on weeks -2, 0, 2, 4, 6, 8, 10, and 12. The %FRC in pre-BMT patients (mean, 0.52%; range, 0.04%-1.56%) was higher than in healthy control subjects (mean, 0.08%; range, 0.02%-0.27%). The highest %FRC (> or = 1.3%) were seen in 2 pre-BMT and 17 post-BMT patients. Eight patients who developed thrombotic microangiopathy (TMA) showed %FRC values that were significantly higher than those in patients without TMA. However, the timing of elevated %FRC was delayed until several days after the onset of intravascular hemolysis and/or a drop in platelet count. Of the patients who did not experience TMA, 5 patients with infection and 4 patients with acute graft-versus-host disease (GVHD) also showed significant elevation of %FRC during the clinical course. Furthermore, multivariate analysis results demonstrated that TMA and infection had a statistically significant effect on the high value of %FRC. These findings indicate that the appearance of FRC is a common phenomenon in patients undergoing BMT and is not a predictive factor for the early diagnosis of TMA, although FRC is one of the main laboratory findings in TMA. Furthermore, an increased %FRC is seen in other post-BMT clinical settings, such as infection and acute GVHD.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Bone Marrow Transplantation - adverse effects</subject><subject>Bone marrow, stem cells transplantation. Graft versus host reaction</subject><subject>Case-Control Studies</subject><subject>Erythrocytes - pathology</subject><subject>Female</subject><subject>Hemolysis</subject><subject>Hemolytic-Uremic Syndrome - blood</subject><subject>Hemolytic-Uremic Syndrome - diagnosis</subject><subject>Hemolytic-Uremic Syndrome - etiology</subject><subject>Humans</subject><subject>Incidence</subject><subject>Infection - blood</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Predictive Value of Tests</subject><subject>Purpura, Thrombotic Thrombocytopenic - blood</subject><subject>Purpura, Thrombotic Thrombocytopenic - diagnosis</subject><subject>Purpura, Thrombotic Thrombocytopenic - etiology</subject><subject>Risk Factors</subject><subject>Time Factors</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><subject>Transplantation, Homologous</subject><issn>0925-5710</issn><issn>1865-3774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpd0E1rGzEQBmBRGhLn49IfUEQhORQ2HUkraXVsTZIGAr2kl1wWrXZkZNaSK60p-fdRsMGQw6ARPAwzLyFfGNwyAP3j1z1w0wnOuk9kwTolG6F1-5kswHDZSM3gjJyXsgZgGlp9Ss4YV1x3Ui7Iy3IKMTg70RJWMfjaRoc0eeqzXW0wzjjSXMvhNBVq_YyZ2mlKK4wYHB1SRLqxOaf_dM42lu1k42znkOIlOfF2Knh1eC_I3_u75-Xv5unPw-Py51PjhBFzo4x2IJgblfOuBTC2ReM7ZIqBQmv4IIeRMaxfYT1zEpQdulG11QKMRlyQm_3cbU7_dljmfhPK-7o2YtqVXgswAG1X4bcPcJ12Odbdes606DgXuqLve-RyKiWj77c51ANfewb9e9z9Me6Kvx4m7oYNjkd6yLeC6wOwpYZcM40ulKNrJQempHgDtQ6Ggg</recordid><startdate>20030201</startdate><enddate>20030201</enddate><creator>KANAMORI, Heiwa</creator><creator>TAKAISHI, Yumiko</creator><creator>ISHIGATSUBO, Yoshiaki</creator><creator>TAKABAYASHI, Maki</creator><creator>TANAKA, Masatsugu</creator><creator>YAMAJI, Satoshi</creator><creator>TOMITA, Naoto</creator><creator>FUJIMAKI, Katsumichi</creator><creator>FUJISAWA, Shin</creator><creator>WATANABE, Shinichiro</creator><creator>MATSUZAKI, Michio</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20030201</creationdate><title>Clinical significance of fragmented red cells after allogeneic bone marrow transplantation</title><author>KANAMORI, Heiwa ; TAKAISHI, Yumiko ; ISHIGATSUBO, Yoshiaki ; TAKABAYASHI, Maki ; TANAKA, Masatsugu ; YAMAJI, Satoshi ; TOMITA, Naoto ; FUJIMAKI, Katsumichi ; FUJISAWA, Shin ; WATANABE, Shinichiro ; MATSUZAKI, Michio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-697c031cd6cfc4009a4e9f8e16106ea92b5bd11e6103af1c506ab8d6440000d93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Bone Marrow Transplantation - adverse effects</topic><topic>Bone marrow, stem cells transplantation. Graft versus host reaction</topic><topic>Case-Control Studies</topic><topic>Erythrocytes - pathology</topic><topic>Female</topic><topic>Hemolysis</topic><topic>Hemolytic-Uremic Syndrome - blood</topic><topic>Hemolytic-Uremic Syndrome - diagnosis</topic><topic>Hemolytic-Uremic Syndrome - etiology</topic><topic>Humans</topic><topic>Incidence</topic><topic>Infection - blood</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Predictive Value of Tests</topic><topic>Purpura, Thrombotic Thrombocytopenic - blood</topic><topic>Purpura, Thrombotic Thrombocytopenic - diagnosis</topic><topic>Purpura, Thrombotic Thrombocytopenic - etiology</topic><topic>Risk Factors</topic><topic>Time Factors</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><topic>Transplantation, Homologous</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KANAMORI, Heiwa</creatorcontrib><creatorcontrib>TAKAISHI, Yumiko</creatorcontrib><creatorcontrib>ISHIGATSUBO, Yoshiaki</creatorcontrib><creatorcontrib>TAKABAYASHI, Maki</creatorcontrib><creatorcontrib>TANAKA, Masatsugu</creatorcontrib><creatorcontrib>YAMAJI, Satoshi</creatorcontrib><creatorcontrib>TOMITA, Naoto</creatorcontrib><creatorcontrib>FUJIMAKI, Katsumichi</creatorcontrib><creatorcontrib>FUJISAWA, Shin</creatorcontrib><creatorcontrib>WATANABE, Shinichiro</creatorcontrib><creatorcontrib>MATSUZAKI, Michio</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KANAMORI, Heiwa</au><au>TAKAISHI, Yumiko</au><au>ISHIGATSUBO, Yoshiaki</au><au>TAKABAYASHI, Maki</au><au>TANAKA, Masatsugu</au><au>YAMAJI, Satoshi</au><au>TOMITA, Naoto</au><au>FUJIMAKI, Katsumichi</au><au>FUJISAWA, Shin</au><au>WATANABE, Shinichiro</au><au>MATSUZAKI, Michio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical significance of fragmented red cells after allogeneic bone marrow transplantation</atitle><jtitle>International journal of hematology</jtitle><addtitle>Int J Hematol</addtitle><date>2003-02-01</date><risdate>2003</risdate><volume>77</volume><issue>2</issue><spage>180</spage><epage>184</epage><pages>180-184</pages><issn>0925-5710</issn><eissn>1865-3774</eissn><abstract>To clarify the clinical significance of the presence of fragmented red cells (FRC) after allogeneic bone marrow transplantation (BMT), we measured the incidence and degree of FRC and their relationships to clinical features. The percentages of FRC (%FRC) were measured in 50 patients on weeks -2, 0, 2, 4, 6, 8, 10, and 12. The %FRC in pre-BMT patients (mean, 0.52%; range, 0.04%-1.56%) was higher than in healthy control subjects (mean, 0.08%; range, 0.02%-0.27%). The highest %FRC (> or = 1.3%) were seen in 2 pre-BMT and 17 post-BMT patients. Eight patients who developed thrombotic microangiopathy (TMA) showed %FRC values that were significantly higher than those in patients without TMA. However, the timing of elevated %FRC was delayed until several days after the onset of intravascular hemolysis and/or a drop in platelet count. Of the patients who did not experience TMA, 5 patients with infection and 4 patients with acute graft-versus-host disease (GVHD) also showed significant elevation of %FRC during the clinical course. Furthermore, multivariate analysis results demonstrated that TMA and infection had a statistically significant effect on the high value of %FRC. These findings indicate that the appearance of FRC is a common phenomenon in patients undergoing BMT and is not a predictive factor for the early diagnosis of TMA, although FRC is one of the main laboratory findings in TMA. Furthermore, an increased %FRC is seen in other post-BMT clinical settings, such as infection and acute GVHD.</abstract><cop>Tokyo</cop><pub>Springer</pub><pmid>12627855</pmid><doi>10.1007/BF02983218</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0925-5710 |
ispartof | International journal of hematology, 2003-02, Vol.77 (2), p.180-184 |
issn | 0925-5710 1865-3774 |
language | eng |
recordid | cdi_proquest_miscellaneous_73090048 |
source | MEDLINE; SpringerLink Journals - AutoHoldings |
subjects | Adolescent Adult Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences Bone Marrow Transplantation - adverse effects Bone marrow, stem cells transplantation. Graft versus host reaction Case-Control Studies Erythrocytes - pathology Female Hemolysis Hemolytic-Uremic Syndrome - blood Hemolytic-Uremic Syndrome - diagnosis Hemolytic-Uremic Syndrome - etiology Humans Incidence Infection - blood Male Medical sciences Middle Aged Predictive Value of Tests Purpura, Thrombotic Thrombocytopenic - blood Purpura, Thrombotic Thrombocytopenic - diagnosis Purpura, Thrombotic Thrombocytopenic - etiology Risk Factors Time Factors Transfusions. Complications. Transfusion reactions. Cell and gene therapy Transplantation, Homologous |
title | Clinical significance of fragmented red cells after allogeneic bone marrow transplantation |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T12%3A46%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20significance%20of%20fragmented%20red%20cells%20after%20allogeneic%20bone%20marrow%20transplantation&rft.jtitle=International%20journal%20of%20hematology&rft.au=KANAMORI,%20Heiwa&rft.date=2003-02-01&rft.volume=77&rft.issue=2&rft.spage=180&rft.epage=184&rft.pages=180-184&rft.issn=0925-5710&rft.eissn=1865-3774&rft_id=info:doi/10.1007/BF02983218&rft_dat=%3Cproquest_cross%3E1879945031%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=217382237&rft_id=info:pmid/12627855&rfr_iscdi=true |